Abbott Laboratories (ABT) official guidance
Abbott Laboratories (ABT) official earnings guidance and management outlook. Each figure management stated is shown with its revisions and the source quote.
See the full Filings Intelligence suiteABTABBOTT LABORATORIESQ4 FY2026 · ends 2026-12-31
2 metrics1 new1 maintainedearnings call · 20d
2026-10-21 14:37:21 UTC$1.62 – $1.67maintained
For the fourth quarter, we forecast adjusted earnings per share of $1.62 to $1.67.
ABT · transcript · Q3 FY2026
2026-10-21 14:36:00 UTCOpen source
2026-10-21 11:36:56 UTC$1.62 – $1.67new
Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.
ABT · EX-99.1 · Q3 FY2026
2026-10-21 11:36:13 UTCOpen source
2026-10-21 14:37:21 UTC-1%new-1% vs Q4 FY2025
Based on current rates, we expect exchange to have a negative impact of approximately 1% on fourth quarter sales.
ABT · transcript · Q3 FY2026
2026-10-21 14:36:00 UTCOpen source
ABTABBOTT LABORATORIESFY2026 · ends 2026-12-31
1 metric1 maintainedearnings call · 20d
2026-10-21 14:37:21 UTC6%maintained6% vs FY2025
The reduction in Q4 for the full year, around 6%, like you said, implies just north of 8%, which is at least accelerating versus where we were in Q3.
ABT · transcript · Q3 FY2026
2026-10-21 14:36:00 UTCOpen source
2026-10-21 11:36:56 UTC6%lowered -14.3%6% vs FY2025
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1.
ABT · EX-99.1 · Q3 FY2026
2026-10-21 11:36:13 UTCOpen source
2026-07-17 04:01:17 UTC6.5% – 7.5%maintained6.5% – 7.5% vs FY2025
Considering our second quarter results and updated outlook for the remainder of the year, we are reaffirming our full year guidance for comparable sales growth of 6.5%-7.5% and raising our EPS guidance range to $5.45-$5.60.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
2026-07-16 11:36:54 UTC6.5% – 7.5%maintained6.5% – 7.5% vs FY2025
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.
ABT · EX-99.1 · Q2 FY2026
2026-07-16 11:36:19 UTCOpen source
2026-04-17 04:01:23 UTC6.5% – 7.5%maintained6.5% – 7.5% vs FY2025
To align with our reporting of comparable sales growth, our full year 2026 sales growth outlook of 6.5%-7.5% is now on a comparable basis as well.
ABT · transcript · Q1 FY2026
2026-04-17 04:00:00 UTCOpen source
2026-04-16 11:36:59 UTC6.5% – 7.5%maintained6.5% – 7.5% vs FY2025
Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.
ABT · EX-99.1 · Q1 FY2026
2026-04-16 11:36:25 UTCOpen source
2026-01-23 05:01:21 UTC6.5% – 7.5%maintained6.5% – 7.5% vs FY2025
For the year, we forecast organic sales growth to be in the range of 6.5%-7.5%.
ABT · transcript · Q4 FY2025
2026-01-23 05:00:00 UTCOpen source
2026-01-22 12:35:57 UTC6.5% – 7.5%lowered -6.7%6.5% – 7.5% vs FY2025
Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.
ABT · EX-99.1 · Q4 FY2025
2026-01-22 12:35:32 UTCOpen source
2025-10-16 04:01:14 UTC7.5%new7.5% vs FY2025
Yeah, Larry. Yeah, I'm very comfortable with consensus. In fact, you know this is a question that was asked last year in our Q3 earnings call, and consensus for 2025 at that time was 7.5%, EPS growth of 10%. That's the same consensus estimates that we have today. I was comfortable with delivering that type of growth at this time last year, and I'm comfortable again today forecasting to deliver that type of growth next year.
ABT · transcript · Q3 FY2025
2025-10-16 04:00:00 UTCOpen source
ABTABBOTT LABORATORIESQ4 FY2026 · ends 2026-12-31
3 metrics3 newearnings call · 20d
2026-10-21 14:37:21 UTCin that low to mid-single rangenew1% – 6% vs Q4 FY2025
If I look into Q4 right now, and probably for the next few quarters, I expect that growth rate to be in that low to mid-single range.
ABT · transcript · Q3 FY2026
2026-10-21 14:36:00 UTCOpen source
2026-10-21 14:37:21 UTC20%new20% vs Q4 FY2025
I think we'll be around 20% in Q4.
ABT · transcript · Q3 FY2026
2026-10-21 14:36:00 UTCOpen source
2026-10-21 14:37:21 UTC8%new8% vs Q4 FY2025
The reduction in Q4 for the full year, around 6%, like you said, implies just north of 8%, which is at least accelerating versus where we were in Q3.
ABT · transcript · Q3 FY2026
2026-10-21 14:36:00 UTCOpen source
ABTABBOTT LABORATORIESFY2026 · ends 2026-12-31
1 metric1 maintainedearnings release · 20d
2026-10-21 11:36:56 UTC$5.5 – $5.55maintained
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.
ABT · EX-99.1 · Q3 FY2026
2026-10-21 11:36:13 UTCOpen source
2026-07-16 11:36:54 UTC$5.45 – $5.6raised +0.8%
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60.
ABT · EX-99.1 · Q2 FY2026
2026-07-16 11:36:19 UTCOpen source
2026-04-17 04:01:23 UTC$5.48maintained
Compared to our previous full year adjusted earnings per share guidance range midpoint of $5.68, our new guidance range midpoint of $5.48 reflects $0.20 of dilution related to the Exact Sciences acquisition, consistent with our assumption at the time of the announced transaction.
ABT · transcript · Q1 FY2026
2026-04-17 04:00:00 UTCOpen source
2026-04-16 11:36:59 UTC$5.38 – $5.58lowered -3.4%
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences.
ABT · EX-99.1 · Q1 FY2026
2026-04-16 11:36:25 UTCOpen source
2026-01-23 05:01:21 UTC$5.55 – $5.8maintained
Turning to our outlook for 2026, today we issued guidance for full-year adjusted earnings per share of $5.55-$5.80, which reflects 10% growth at the midpoint of the range and contemplates an adjusted earnings per share forecast of $1.12-$1.18 for the first quarter.
ABT · transcript · Q4 FY2025
2026-01-23 05:00:00 UTCOpen source
2026-01-22 12:35:57 UTC$5.55 – $5.8new
Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 adjusted diluted earnings per share of $1.12 to $1.18.
ABT · EX-99.1 · Q4 FY2025
2026-01-22 12:35:32 UTCOpen source
ABTABBOTT LABORATORIESQ3 FY2026 · ends 2026-09-30
1 metric1 maintainedearnings call · 2026-07-17 04:01:17 UTC
2026-07-17 04:01:17 UTC$1.38 – $1.46maintained
For the third quarter, we forecast adjusted earnings per share of $1.38-$1.46.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
2026-07-16 11:36:54 UTC$1.38 – $1.46new
Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46.
ABT · EX-99.1 · Q2 FY2026
2026-07-16 11:36:19 UTCOpen source
ABTABBOTT LABORATORIESFY2026 · ends 2026-12-31
1 metric1 maintainedearnings call · 2026-07-17 04:01:17 UTC
2026-07-17 04:01:17 UTC1%maintained
Based on current rates, we expect exchange to have a positive impact of approximately 1% on full year sales, which includes our expectation for exchange to have a negative impact of approximately 1% on third quarter sales.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
2026-04-17 04:01:23 UTC1%maintained
Based on current rates, we expect exchange to have a favorable impact of approximately 1% on full year reported sales.
ABT · transcript · Q1 FY2026
2026-04-17 04:00:00 UTCOpen source
2026-01-23 05:01:21 UTC1%new
Based on current rates, we expect exchange to have a favorable impact of around 1% on full-year reported sales, which includes an expected favorable impact around 3% on first-quarter reported sales.
ABT · transcript · Q4 FY2025
2026-01-23 05:00:00 UTCOpen source
ABTABBOTT LABORATORIESQ3 FY2026 · ends 2026-09-30
1 metric1 newearnings call · 2026-07-17 04:01:17 UTC
2026-07-17 04:01:17 UTC-1%new
Based on current rates, we expect exchange to have a positive impact of approximately 1% on full year sales, which includes our expectation for exchange to have a negative impact of approximately 1% on third quarter sales.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
ABTABBOTT LABORATORIESH4 FY2026 · ends 2026-12-31
1 metric1 newearnings call · 2026-07-17 04:01:17 UTC
2026-07-17 04:01:17 UTChigher than the first halfnew
We continue to expect cancer diagnostics growth in the second half of the year to be higher than the first half, supported by increasing volumes from care gap programs, recently launched tests, and continued international adoption.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
ABTABBOTT LABORATORIESFY2026 · ends 2026-12-31
1 metric1 maintainedearnings call · 2026-07-17 04:01:17 UTC
2026-07-17 04:01:17 UTCa decline in the China business, but much, much lower, mid-single digitsmaintained-6% – -4% vs FY2025
We're still forecasting a decline in the China business, but much, much lower, mid-single digits.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
2026-04-17 04:01:23 UTCa single-digit decline for the yearnew-9% – -1% vs FY2025
I think the impact here is we've got China modeled in at a single-digit decline for the year.
ABT · transcript · Q1 FY2026
2026-04-17 04:00:00 UTCOpen source
ABTABBOTT LABORATORIESH4 FY2026 · ends 2026-12-31
1 metric1 newearnings call · 2026-07-17 04:01:17 UTC
2026-07-17 04:01:17 UTCaccelerate in the second halfnew
I expect global EP growth to accelerate. It's in the teens right now. It'll accelerate in the second half for sure and outperforming the market.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
ABTABBOTT LABORATORIESFY2026 · ends 2026-12-31
3 metrics1 lowered2 newearnings call · 2026-07-17 04:01:17 UTC
2026-07-17 04:01:17 UTCmid-teensnew14% – 16% vs FY2025
Our deal model that we put together to support the acquisition for 2026 had mid-teens. I feel confident that we'll achieve that.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
2026-07-17 04:01:17 UTC2% – 4%new2% – 4% vs FY2025
There's a lot of proof points here, Joanne, in terms of being able to feel confident about not only the acceleration in the second half, but establishing this kind of 2%-4% range here for this business.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
2026-07-17 04:01:17 UTCmid to high single-digit growth ratelowered -18.8%4% – 9% vs FY2025
Yeah. Listen, I expect structural heart by the end of this year to be in that kind of mid to high single-digit growth rate back to where we were before.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
2026-04-17 04:01:23 UTChigh single-digit%new7% – 9% vs FY2025
I continue to expect our structural heart growth here to be high single-digit% for the full year.
ABT · transcript · Q1 FY2026
2026-04-17 04:00:00 UTCOpen source
ABTABBOTT LABORATORIESH4 FY2026 · ends 2026-12-31
1 metricearnings call · 2026-07-17 04:01:17 UTC
2026-07-17 04:01:17 UTCsales growth acceleration
We have momentum building across the portfolio and clear line of sight to the key drivers of sales growth acceleration that are forecasted in the second half.
ABT · transcript · Q2 FY2026
2026-07-17 04:00:00 UTCOpen source
2026-04-17 04:01:23 UTCacceleration in growth in the second halfnew
We remain confident in our expectation for an acceleration in growth in the second half of the year.
ABT · transcript · Q1 FY2026
2026-04-17 04:00:00 UTCOpen source
ABTABBOTT LABORATORIESQ2 FY2026 · ends 2026-06-30
2 metrics1 new1 maintainedearnings call · 2026-04-17 04:01:23 UTC
2026-04-17 04:01:23 UTC$1.25 – $1.31maintained
For the second quarter, we forecast adjusted earnings per share of $1.25-$1.31.
ABT · transcript · Q1 FY2026
2026-04-17 04:00:00 UTCOpen source
2026-04-16 11:36:59 UTC$1.25 – $1.31new
Abbott projects second-quarter 2026 adjusted diluted earnings per share of $1.25 to $1.31.
ABT · EX-99.1 · Q1 FY2026
2026-04-16 11:36:25 UTCOpen source
2026-04-17 04:01:23 UTCrelatively neutral impact on salesnew
For the second quarter, we expect exchange to have relatively neutral impact on sales.
ABT · transcript · Q1 FY2026
2026-04-17 04:00:00 UTCOpen source
ABTABBOTT LABORATORIESFY2026 · ends 2026-12-31
1 metric1 newearnings call · 2026-04-17 04:01:23 UTC
2026-04-17 04:01:23 UTC$3Bnew
As we communicated at the time of the acquisition announcement, we forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026 and accelerate Abbott's long-term sales growth rate.
ABT · transcript · Q1 FY2026
2026-04-17 04:00:00 UTCOpen source